Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink R, van Gerwen B, Féliz L, Abou-Alfa GK, Ross JS, van de Ven M, Rottenberg S, Cuppen E, Chessex AV, Ali SM, Burn TC, Jimenez CR, Ganesan S, Wessels LFA, Jonkers J. Zingg D, et al. Among authors: siteur b. Nature. 2022 Aug;608(7923):609-617. doi: 10.1038/s41586-022-05066-5. Epub 2022 Aug 10. Nature. 2022. PMID: 35948633 Free PMC article. Clinical Trial.
Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.
Zingg D, Bhin J, Yemelyanenko J, Kas SM, Rolfs F, Lutz C, Lee JK, Klarenbeek S, Silverman IM, Annunziato S, Chan CS, Piersma SR, Eijkman T, Badoux M, Gogola E, Siteur B, Sprengers J, de Klein B, de Goeij-de Haas RR, Riedlinger GM, Ke H, Madison R, Drenth AP, van der Burg E, Schut E, Henneman L, van Miltenburg MH, Proost N, Zhen H, Wientjens E, de Bruijn R, de Ruiter JR, Boon U, de Korte-Grimmerink R, van Gerwen B, Féliz L, Abou-Alfa GK, Ross JS, van de Ven M, Rottenberg S, Cuppen E, Chessex AV, Ali SM, Burn TC, Jimenez CR, Ganesan S, Wessels LFA, Jonkers J. Zingg D, et al. Among authors: siteur b. Nature. 2022 Sep;609(7929):E13. doi: 10.1038/s41586-022-05287-8. Nature. 2022. PMID: 36050473 Free PMC article. No abstract available.
Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.
Annunziato S, de Ruiter JR, Henneman L, Brambillasca CS, Lutz C, Vaillant F, Ferrante F, Drenth AP, van der Burg E, Siteur B, van Gerwen B, de Bruijn R, van Miltenburg MH, Huijbers IJ, van de Ven M, Visvader JE, Lindeman GJ, Wessels LFA, Jonkers J. Annunziato S, et al. Among authors: siteur b. Nat Commun. 2019 Jan 23;10(1):397. doi: 10.1038/s41467-019-08301-2. Nat Commun. 2019. PMID: 30674894 Free PMC article.
In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.
Annunziato S, Lutz C, Henneman L, Bhin J, Wong K, Siteur B, van Gerwen B, de Korte-Grimmerink R, Zafra MP, Schatoff EM, Drenth AP, van der Burg E, Eijkman T, Mukherjee S, Boroviak K, Wessels LF, van de Ven M, Huijbers IJ, Adams DJ, Dow LE, Jonkers J. Annunziato S, et al. Among authors: siteur b. EMBO J. 2020 Mar 2;39(5):e102169. doi: 10.15252/embj.2019102169. Epub 2020 Jan 13. EMBO J. 2020. PMID: 31930530 Free PMC article.
Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland.
Annunziato S, Kas SM, Nethe M, Yücel H, Del Bravo J, Pritchard C, Bin Ali R, van Gerwen B, Siteur B, Drenth AP, Schut E, van de Ven M, Boelens MC, Klarenbeek S, Huijbers IJ, van Miltenburg MH, Jonkers J. Annunziato S, et al. Among authors: siteur b. Genes Dev. 2016 Jun 15;30(12):1470-80. doi: 10.1101/gad.279190.116. Genes Dev. 2016. PMID: 27340177 Free PMC article.
Division of labor within the DNA damage tolerance system reveals non-epistatic and clinically actionable targets for precision cancer medicine.
Spanjaard A, Shah R, de Groot D, Buoninfante OA, Morris B, Lieftink C, Pritchard C, Zürcher LM, Ormel S, Catsman JJI, de Korte-Grimmerink R, Siteur B, Proost N, Boadum T, van de Ven M, Song JY, Kreft M, van den Berk PCM, Beijersbergen RL, Jacobs H. Spanjaard A, et al. Among authors: siteur b. Nucleic Acids Res. 2022 Jul 22;50(13):7420-7435. doi: 10.1093/nar/gkac545. Nucleic Acids Res. 2022. PMID: 35819193 Free PMC article.
Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.
Ratz L, Brambillasca C, Bartke L, Huetzen MA, Goergens J, Leidecker O, Jachimowicz RD, van de Ven M, Proost N, Siteur B, de Korte-Grimmerink R, Bouwman P, Pulver EM, de Bruijn R, Isensee J, Hucho T, Pandey G, van Lohuizen M, Mallmann P, Reinhardt HC, Jonkers J, Puppe J. Ratz L, et al. Among authors: siteur b. Breast Cancer Res. 2022 Jun 17;24(1):41. doi: 10.1186/s13058-022-01534-y. Breast Cancer Res. 2022. PMID: 35715861 Free PMC article.
11 results